0.704
price down icon0.56%   -0.004
after-market Handel nachbörslich: .69 -0.014 -1.99%
loading
Schlusskurs vom Vortag:
$0.708
Offen:
$0.708
24-Stunden-Volumen:
183.15K
Relative Volume:
0.13
Marktkapitalisierung:
$4.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.27M
KGV:
-0.0329
EPS:
-21.4132
Netto-Cashflow:
$-9.40M
1W Leistung:
-3.83%
1M Leistung:
-17.66%
6M Leistung:
-41.82%
1J Leistung:
-81.07%
1-Tages-Spanne:
Value
$0.68
$0.75
1-Wochen-Bereich:
Value
$0.6611
$0.758
52-Wochen-Spanne:
Value
$0.6611
$5.00

Dermata Therapeutics Inc Stock (DRMA) Company Profile

Name
Firmenname
Dermata Therapeutics Inc
Name
Telefon
(858)-223-0882
Name
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-15
Name
Neueste SEC-Einreichungen
Name
DRMA's Discussions on Twitter

Vergleichen Sie DRMA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DRMA
Dermata Therapeutics Inc
0.704 4.67M 0 -11.27M -9.40M -21.41
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.00 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.82 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.282 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.54 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
483.07 65.36B 14.09B 4.50B 2.96B 39.28

Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten

pulisher
Jun 04, 2025

Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Dermata stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Dermata stock hits 52-week low at $0.69 amid market challenges - Investing.com Australia

Jun 03, 2025
pulisher
May 30, 2025

Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 57.0% in May - Defense World

May 30, 2025
pulisher
May 29, 2025

Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 2% – Time to Sell? - Defense World

May 29, 2025
pulisher
May 23, 2025

Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $3.00 - Defense World

May 23, 2025
pulisher
May 21, 2025

Dermata gears up for phase 3 trial of XYNGARI By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

Maxim Group cuts Dermata Therapeutics target to $3 By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

Dermata gears up for phase 3 trial of XYNGARI - Investing.com

May 21, 2025
pulisher
May 21, 2025

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial - TipRanks

May 21, 2025
pulisher
May 21, 2025

Dermata Therapeutics IncPotential NDA Filing For Xyngari In H1 2028SEC Filing - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Maxim Group cuts Dermata Therapeutics target to $3 - Investing.com

May 21, 2025
pulisher
May 21, 2025

Dermata Therapeutics (DRMA) Price Target Cut Amid Capital Raise - GuruFocus

May 21, 2025
pulisher
May 16, 2025

Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks

May 16, 2025
pulisher
May 14, 2025

Dermata (DRMA) Achieves Positive Phase 3 Trial Results for Acne Treatment | DRMA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

DRMA: Substantial Cash Increase Enhances Financial Stability | DRMA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Dermata Reports Positive Phase 3 Trial Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire

May 14, 2025
pulisher
May 14, 2025

Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Revolutionary Once-Weekly Natural Acne Treatment Achieves Breakthrough in Phase 3 Trial Results - Stock Titan

May 14, 2025
pulisher
May 03, 2025

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire

May 03, 2025
pulisher
Apr 28, 2025

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 26, 2025

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 24, 2025

DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 16, 2025

Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia

Apr 16, 2025
pulisher
Apr 15, 2025

Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata reports early success in acne treatment with XYNGARI - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com

Apr 09, 2025
pulisher
Apr 04, 2025

Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 04, 2025
pulisher
Apr 01, 2025

Dermata Therapeutics stock hits 52-week low at $1 - Investing.com

Apr 01, 2025
pulisher
Mar 28, 2025

Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph

Mar 27, 2025

Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Kapitalisierung:     |  Volumen (24h):